{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:57:16Z","timestamp":1771030636751,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jchromb.2024.124436","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T16:22:43Z","timestamp":1735402963000},"page":"124436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development and optimization of a high-throughput HPLC-MS\/MS method for the simultaneous determination of Cedazuridine, Gemcitabine and its metabolite in mouse plasma"],"prefix":"10.1016","volume":"1252","author":[{"given":"Qing","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxia","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qikun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124436_b0005","first-page":"4","article-title":"Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials","author":"Wang","year":"2016","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.jchromb.2024.124436_b0010","doi-asserted-by":"crossref","DOI":"10.18063\/cp.v3i3.323","article-title":"Gemcitabine for Pancreatic Cancer Therapy","volume":"3","author":"Srivani","year":"2024","journal-title":"Cancer plus"},{"issue":"3","key":"10.1016\/j.jchromb.2024.124436_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.breast.2007.10.009","article-title":"Role of gemcitabine in metastatic breast cancer patients: A short review","volume":"17","author":"Silvestris","year":"2008","journal-title":"Breast"},{"key":"10.1016\/j.jchromb.2024.124436_b0020","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.2147\/IJN.S212978","article-title":"RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jchromb.2024.124436_b0025","doi-asserted-by":"crossref","unstructured":"G.J. Petersa C L V D W, C.J.A. Van Moorsela, J.R. Kroepa, A.M. Bergmana, S.P. Acklandb. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacology & Therapeutics, (2000), 87: 227-53. DOI: 10.1016\/S0163-7258(00)00086-3.","DOI":"10.1016\/S0163-7258(00)00086-3"},{"key":"10.1016\/j.jchromb.2024.124436_b0030","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.2147\/OTT.S210117","article-title":"Prolonged low-dose infusion for gemcitabine: a systematic review","volume":"12","author":"Zhao","year":"2019","journal-title":"OncoTargets and Therapy"},{"key":"10.1016\/j.jchromb.2024.124436_b0035","first-page":"273","article-title":"N-trimethyl chitosan coated nano-complexes enhance the oral bioavailability and chemotherapeutic effects of gemcitabine","author":"Chen","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jchromb.2024.124436_b0040","first-page":"180","article-title":"Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice","author":"Thompson","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124436_b0045","first-page":"592","article-title":"Recent advances and prospects in gemcitabine drug delivery systems","author":"Paroha","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jchromb.2024.124436_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/scipharm86040043","article-title":"Pharmacokinetic Enhancers (Boosters)\u2014Escort for Drugs against Degrading Enzymes and Beyond","volume":"86","author":"Krau\u00df","year":"2018","journal-title":"Sci. Pharm."},{"issue":"11","key":"10.1016\/j.jchromb.2024.124436_b0055","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-07-4885","article-title":"Modulation of Gemcitabine (2\u2032,2\u2032-Difluoro-2\u2032-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine","volume":"14","author":"Beumer","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jchromb.2024.124436_b0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-007-0625-2","article-title":"Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice","volume":"62","author":"Beumer","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.jchromb.2024.124436_b0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-010-1337-6","article-title":"Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice","volume":"67","author":"Beumer","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.jchromb.2024.124436_b0070","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm401856k","article-title":"Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase","volume":"57","author":"Ferraris","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.jchromb.2024.124436_b0075","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14737140.2021.1918002","article-title":"The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era","volume":"21","author":"Schiffer","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"16","key":"10.1016\/j.jchromb.2024.124436_b0080","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2217\/fon-2020-1210","article-title":"Role of cedazuridine\/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"17","author":"Swapna Thota","year":"2021","journal-title":"Future Oncol."},{"issue":"13","key":"10.1016\/j.jchromb.2024.124436_b0085","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/Cedazuridine: First Approval","volume":"80","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jchromb.2024.124436_b0090","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.jchromb.2024.124436_b0095","article-title":"A Systematic Analytical Quality By Design Approach For Estimation Of Decitabine And Cedazuridine Combined Pharmaceutical Formulations Using RP-HPLC","volume":"13","author":"Ramyasree","year":"2022","journal-title":"J. Pharmaceut. Negative Results"},{"key":"10.1016\/j.jchromb.2024.124436_b0100","first-page":"10","article-title":"RP-HPLC-PDA Method Development, Validation and Stability Studies of the Novel Antineoplastic Drug Combination - Decitabine and Cedazuridine","author":"Prakash","year":"2020","journal-title":"J. Pharm. Res.International"},{"issue":"2","key":"10.1016\/j.jchromb.2024.124436_b0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11523-020-00709-x","article-title":"Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model","volume":"15","author":"Ramsey","year":"2020","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jchromb.2024.124436_b0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jchromb.2018.03.025","article-title":"Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2\u2032, 2\u2032-difluorodeoxyuridine in rat plasma by UFLC-MS\/MS","volume":"1084","author":"Sun","year":"2018","journal-title":"J. Chromatogr. B"},{"issue":"6","key":"10.1016\/j.jchromb.2024.124436_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/medicina60060864","article-title":"Development and Validation of a Simple and Reliable HPLC-UV Method for Determining Gemcitabine Levels: Application in Pharmacokinetic Analysis","volume":"60","author":"Lafazanis","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.jchromb.2024.124436_b0120","first-page":"610","article-title":"HPLC methods for quantifying anticancer drugs in human samples: A systematic review","author":"Sabourian","year":"2020","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2024.124436_b0125","first-page":"198","article-title":"LC-MS\/MS method for quantitation of gemcitabine and its metabolite 2\u2032,2\u2032-difluoro-2\u2032-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study","author":"Zhong","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"22","key":"10.1016\/j.jchromb.2024.124436_b0130","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.jchromb.2009.06.002","article-title":"Development of a sensitive and selective LC\u2013MS\/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma","volume":"877","author":"Bowen","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2024.124436_b0135","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, Guidance for Industry Bioanalytical Method Validation (2018)."},{"key":"10.1016\/j.jchromb.2024.124436_b0140","first-page":"206","article-title":"Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS\/MS coupled with pre-column derivatization and MSALL technique","author":"Yin","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2024.124436_b0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jpba.2017.12.048","article-title":"Ultra-sensitive LC\u2013MS\/MS method for the quantification of gemcitabine and its metabolite 2\u2032,2\u2032-difluorodeoxyuridine in human plasma for a microdose clinical trial","volume":"151","author":"van Nuland","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1\u20132","key":"10.1016\/j.jchromb.2024.124436_b0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchromb.2006.03.023","article-title":"High-performance liquid chromatographic method for the determination of gemcitabine and 2\u2032,2\u2032-difluorodeoxyuridine in plasma and tissue culture media","volume":"835","author":"Kirstein","year":"2006","journal-title":"J. Chromatogr. B"},{"issue":"1\u20132","key":"10.1016\/j.jchromb.2024.124436_b0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2004.09.012","article-title":"Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography","volume":"813","author":"Zhao","year":"2004","journal-title":"J. Chromatogr. B"},{"issue":"3","key":"10.1016\/j.jchromb.2024.124436_b0160","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/bmc.3562","article-title":"A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5\u2010azacytidine","volume":"30","author":"Anders","year":"2015","journal-title":"Biomed. Chromatogr."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T02:23:15Z","timestamp":1738462995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S1570023224004458"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124436","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and optimization of a high-throughput HPLC-MS\/MS method for the simultaneous determination of Cedazuridine, Gemcitabine and its metabolite in mouse plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124436"}}